Evidence map›Paper›PMID 33737637›Full record

ArticleScientific reports2021

Folate transporter dynamics and therapy with classic and tumor-targeted antifolates.

Carrie O'Connor, Adrianne Wallace-Povirk, Changwen Ning, Josephine Frühauf, Nian Tong, Aleem Gangjee, Larry H Matherly, Zhanjun Hou

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. International journal of molecular medicine · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Prodrug Approach as a Strategy to Enhance Drug Permeability.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. How Cryo-EM Has Expanded Our Understanding of Membrane Transporters.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Biology and therapeutic applications of the proton-coupled folate transporter.Expert opinion on drug metabolism & toxicology · 2022
    Article
  19. Article
  20. The evolving biology of the proton-coupled folate transporter: New insights into regulation, structure, and mechanism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Carrie O'ConnorDepartments of Oncology, Wayne State University School of Medicine, 421 E. Canfield, Detroit, MI, 48201, USA.
Adrianne Wallace-PovirkDepartments of Oncology, Wayne State University School of Medicine, 421 E. Canfield, Detroit, MI, 48201, USA.
Changwen NingDepartments of Oncology, Wayne State University School of Medicine, 421 E. Canfield, Detroit, MI, 48201, USA.
Josephine FrühaufDepartments of Oncology, Wayne State University School of Medicine, 421 E. Canfield, Detroit, MI, 48201, USA.
Nian TongDivision of Medicinal Chemistry, Duquesne University, Pittsburgh, PA, USA.
Aleem GangjeeDivision of Medicinal Chemistry, Duquesne University, Pittsburgh, PA, USA.
Larry H MatherlyDepartments of Oncology, Wayne State University School of Medicine, 421 E. Canfield, Detroit, MI, 48201, USA. matherly@karmanos.org.
Zhanjun HouDepartments of Oncology, Wayne State University School of Medicine, 421 E. Canfield, Detroit, MI, 48201, USA. houz@karmanos.org.
Wayne State University · USDuquesne University · USThe Barbara Ann Karmanos Cancer Institute · US

Funding

MOLECULAR REGULATION OF FOLATE AND ANTIFOLATE TRANSPORTR01CA053535 · NCI · WAYNE STATE UNIVERSITY · PI HOU, ZHANJUN, MATHERLY, LARRY H · 1993 to 2024
$6.3M
TRAINING PROGRAM IN THE BIOLOGY OF CANCERT32CA009531 · NCI · WAYNE STATE UNIVERSITY · PI Larry H Matherly · 1985 to 2026
$5.3M
Discovery of novel PCFT-targeted agentsR01CA152316 · NCI · WAYNE STATE UNIVERSITY · PI GANGJEE, ALEEM, MATHERLY, LARRY H · 2011 to 2015
$2.3M
Purine Synthesis Inhibitors with Selective Folate Receptor Tumor TransportR01CA166711 · NCI · DUQUESNE UNIVERSITY · PI DANN, CHARLES E., GANGJEE, ALEEM · 2013 to 2015
$1.7M
Targeting Mitochondrial One-Carbon Metabolism in Epithelial Ovarian CancerF31CA243215 · NCI · WAYNE STATE UNIVERSITY · PI WALLACE-POVIRK, ADRIANNE · 2019 to 2020
$85k
NCI NIH HHS F31 CA243215NCI NIH HHS R01 CA053535NCI NIH HHS R01 CA152316NCI NIH HHS R01 CA166711NCI NIH HHS T32 CA009531
6 · The paper itself

Abstract

There are three major folate uptake systems in human tissues and tumors, including the reduced folate carrier (RFC), folate receptors (FRs) and proton-coupled folate transporter (PCFT). We studied the functional interrelationships among these systems for the novel tumor-targeted antifolates AGF94 (transported by PCFT and FRs but not RFC) and AGF102 (selective for FRs) versus the classic antifolates pemetrexed, methotrexate and PT523 (variously transported by FRs, PCFT and RFC). We engineered HeLa cell models to express FRα or RFC under control of a tetracycline-inducible promoter with or without constitutive PCFT. We showed that cellular accumulations of extracellular folates were determined by the type and levels of the major folate transporters, with PCFT and RFC prevailing over FRα, depending on expression levels and pH. Based on patterns of cell proliferation in the presence of the inhibitors, we established transport redundancy for RFC and PCFT in pemetrexed uptake, and for PCFT and FRα in AGF94 uptake; uptake by PCFT predominated for pemetrexed and FRα for AGF94. For methotrexate and PT523, uptake by RFC predominated even in the presence of PCFT or FRα. For both classic (methotrexate, PT523) and FRα-targeted (AGF102) antifolates, anti-proliferative activities were antagonized by PCFT, likely due to its robust activity in mediating folate accumulation. Collectively, our findings describe a previously unrecognized interplay among the major folate transport systems that depends on transporter levels and extracellular pH, and that determines their contributions to the uptake and anti-tumor efficacies of targeted and untargeted antifolates.

Indexed as

Biological TransportCell ProliferationFolate Receptor 1Folic AcidFolic Acid AntagonistsHeLa CellsHumansMethotrexateNeoplasmsOrnithinePemetrexedProton-Coupled Folate TransporterPterinsReduced Folate Carrier ProteinFolate Receptor 1Folic AcidFolic Acid AntagonistsMethotrexateN(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithineOrnithinePemetrexedProton-Coupled Folate TransporterPterinsReduced Folate Carrier ProteinSLC46A1 protein, human

Identifiers

PMID33737637
PMCPMC7973545
OpenAlexW3136027982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.